Glycine antagonist in neuroprotection for patients with acute stroke gain americas: A randomized controlled trial

JAMA

Volumn 285, Issue 13, 2001, Pages 1719-1728

  Sacco, Ralph L ^a   DeRosa, Janet T ^a   Haley, E Clarke ^b   Levin, Bruce ^a   Ordronneau, Paul ^c   Phillips, Stephen J ^d   Rundek, Tanja ^a   Snipes, Rose G ^c   Thompson, John L P ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAVESTINEL; GLYCINE RECEPTOR ANTAGONIST;

ADULT; AGED; AGITATION; ARTICLE; ASPIRATION PNEUMONIA; BRAIN HERNIA; BRAIN PERFUSION; CELL DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE DEPOLARIZATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TACHYCARDIA; TARGET CELL;

EID: 0035804844     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.13.1719     Document Type: Article

References (37)

1. Thresholds in cerebral ischemia: The ischemic penumbra
2. Viability thresholds and the penumbra of focal ischemia
3. Clinical trials with neuroprotective drugs in acute ischemic stroke
4. Termination of acute stroke studies involving selfotel treatment
5. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke
6. The effects of lifarizine in acute cerebral infarction
7. Identification and pharmacological characterization of GV150526, a novel glycine antagonist as a potent neuroprotective agent
8. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat
9. Safety and tolerability of GV150526 in acute stroke (GLYB2002)
10. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke
11. Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American experience
12. Improved reliability of the NIH stroke scale using video training
13. Relationship of 6-month functional outcome and stroke severity: Implications for acute stroke trials from the Northern Manhattan Stroke Study
14. Interobserver agreement for the assessment of handicap in stroke patients
15. Classification and natural history of clinically identifiable subtypes of cerebral infarction
16. Classifications of subtype of acute ischemic stroke
17. Functional evaluation: The Barthel Index
18. Stroke rehabilitation: Analysis of repeated Barthel Index measures
19. Tissue plasminogen activator for acute ischemic stroke
20. The effect of GV150526 on ischemic lesion volume: The GAIN Americas and GAIN International MRI Substudy
21. The stroke impact scale version 2.0: Evaluation of reliability, validity, and sensitivity to change
22. Chi-Square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure
23. Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
24. Statistical aspects of the analysis of data from retrospective studies of disease
25. Analysis of categorical data by linear models
26. Glycine antagonist (gavestinel) in neuroprotection (GAIN International)in patients with acute stroke
27. Cervene in acute ischemic stroke
28. Cervene (nalmefene) in acute ischemic stroke
29. Combination therapy stroke trial: Rt-PA±lubeluzole
30. Lubeluzole treatment of acute ischemic stroke
31. A randomized efficacy trial of citicholine in patients with acute ischemic stroke
32. Use of the Barthel Index and Modified Rankin Scale in acute stroke trials
33. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke
34. A randomized trial of tirilizad mesylate in patients with acute stroke (RANTTAS)
35. Treatment of acute ischemic stroke with piracetam
36. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
37. The neuroprotectant, GV150526, penetrates the cerebrospinal fluid following treatment of acute stroke